Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy.

Raja RamachandranJoyita BharatiIndu Ramachandra RaoAhmed W KashifRitambhra NadaRanjana MinzKrishan L GuptaHarbir S Kohli

Published in: Nephrology (Carlton, Vic.) (2019)

CD-19 targeted rituximab is a safe and cost-effective agent in remission maintenance in adults with CNI dependent. Over three-fourths of the patients with CNI-dependent podocytopathy maintain clinical remission with CD-19 targeted rituximab therapy.

Keyphrases

diffuse large b cell lymphoma
disease activity
ulcerative colitis
hodgkin lymphoma
cancer therapy
nk cells
stem cells
systemic lupus erythematosus
mesenchymal stem cells